Identification of TAT as a Biomarker Involved in Cell Cycle and DNA Repair in Breast Cancer
Biomolecules · 2024
DOI: 10.3390/biom14091088 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2024. Verfasst von Fei Xie und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tia…. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Cell Cycle, Triple Negative Breast Neoplasms, Tyrosine Transaminase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Nature Science Foundation of China, Natural Science Foundation of Tianjin, Central Universities of Nankai University.
Abstract (Originalsprache)
Breast cancer (BC) is the most frequently diagnosed cancer and the primary cause of cancer-related mortality in women. Treatment of triple-negative breast cancer (TNBC) remains particularly challenging due to its resistance to chemotherapy and poor prognosis. Extensive research efforts in BC screening and therapy have improved clinical outcomes for BC patients. Therefore, identifying reliable biomarkers for TNBC is of great clinical importance. Here, we found that tyrosine aminotransferase (TAT) expression was significantly reduced in BC and strongly correlated with the poor prognosis of BC patients, which distinguished BC patients from normal individuals, indicating that TAT is a valuable biomarker for early BC diagnosis. Mechanistically, we uncovered that methylation of the TAT promoter was significantly increased by DNA methyltransferase 3 (DNMT3A/3B). In addition, reduced TAT contributes to DNA replication and cell cycle activation by regulating homologous recombination repair and mismatch repair to ensure genomic stability, which may be one of the reasons for TNBC resistance to chemotherapy. Furthermore, we demonstrated that Diazinon increases TAT expression as an inhibitor of DNMT3A/3B and inhibits the growth of BC by blocking downstream pathways. Taken together, we revealed that TAT is silenced by DNMT3A/3B in BC, especially in TNBC, which promotes the proliferation of tumor cells by supporting DNA replication, activating cell cycle, and enhancing DNA damage repair. These results provide fresh insights and a theoretical foundation for the clinical diagnosis and treatment of BC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300350, China.
- Cardiothoracic Surgery Department, Characteristic Medical Center of the Chinese People's Armed Police Force, Tianjin 300162, China.
- Department of Pathology, Characteristic Medical Center of The Chinese People's Armed Police Force, Tianjin 300162, China.
ORCID-Profile: Fei Xie, Changliang Shan
Förderung
- National Nature Science Foundation of China
- Natural Science Foundation of Tianjin
- Central Universities of Nankai University
- State Key Laboratory of Drug Research
Zitieren
APA
Xie, F., Hua, S., Guo, Y., Wang, T., Shan, C., Zhang, L., & He, T. (2024). Identification of TAT as a Biomarker Involved in Cell Cycle and DNA Repair in Breast Cancer. Biomolecules. https://doi.org/10.3390/biom14091088
Vancouver
Xie F, Hua S, Guo Y, Wang T, Shan C, Zhang L, et al. Identification of TAT as a Biomarker Involved in Cell Cycle and DNA Repair in Breast Cancer. Biomolecules. 2024. doi:10.3390/biom14091088
BibTeX
@article{Xie2024,
author = {Xie, Fei and Hua, Saiwei and Guo, Yajuan and Wang, Taoyuan and Shan, Changliang and Zhang, Lianwen and He, Tao},
title = {Identification of TAT as a Biomarker Involved in Cell Cycle and DNA Repair in Breast Cancer},
journal = {Biomolecules},
year = {2024},
doi = {10.3390/biom14091088}
}
EUVIMED